Recipharm launches new service to support companies with QC and analytical requirements

1 Nov 2019

Services including method development, method validation, and stability program design and implementation.

CDMO Recipharm has launched Recipharm Analytical Solutions, a stand-alone service to support pharmaceutical companies with their quality control (QC) and analytical requirements.

Recipharm launches new service to support companies with QC and analytical requirements

Recipharm Analytical Solutions, which launches at CPhI Worldwide (5–7 November, Frankfurt, Germany), offers analytical services including method development, method validation, and stability program design and implementation.

The newly launched solution leverages Recipharm’s vast experience and the scale of its laboratories to offer additional capacity to QC and analytical laboratories facing resource challenges, while also aiming to reduce timelines and costs.

The service launches as Recipharm opens a brand-new analytical chemistry laboratory and additional stability walk-in chambers at its facility in Bengaluru, India. This laboratory in Bengaluru, which is the 9th addition to Recipharm’s overall global analytical solutions offering and was commissioned in response to customer demand and became operational in October.

Commenting on the announcement, Dr Ramesh Jagadeesan, Director of Analytical Development at Recipharm said: “Reducing time to market is a key consideration throughout every stage of drug development. By taking an innovative approach to analytical chemistry and using our expertise and capacity, we can improve efficiencies and reduce vital timelines for our customers. For example, worldwide, we are more than 160 analytical scientists that can perform analyses in parallel, share experience of all sorts of molecules and formulations and have the time to focus on finding solutions to customer challenges.”

“Many customers place their full stability programs with us, thus offloading their own QC labs, giving them capacity to focus on core activities.”

“Our understanding of the entire drug development and manufacturing process delivers many benefits, including the ability to develop robust methods made for the stream-lined conditions within QC labs. We are used to working closely with formulation development teams with regulatory implications in mind. We also understand the logistics involved in the scale-up and tech transfer of a drug product, meaning transferring analytical methods should never be an issue.”

Read More

Related news

CDMOs to benefit from rising BTDs, orphan drugs and fast track status therapies

CDMOs to benefit from rising BTDs, orphan drugs and fast track status therapies

8 Nov 2019

But personalized medicines will require new logistics and manufacturing systems.

Read more 
FDA approves first  and only medicine in a new class of acute treatment for migraine

FDA approves first and only medicine in a new class of acute treatment for migraine

15 Oct 2019

The approval of Eli Lilly's Reyvow represents the first new class of acute migraine treatment approved by the FDA in more than two decades.

Read more 
Lonza’s Ibex solutions to support Genmab’s growing clinical portfolio

Lonza’s Ibex solutions to support Genmab’s growing clinical portfolio

14 Oct 2019

Company's Ibex Design planned to take Genmab’s pre-clinical candidates from gene to potential IND within 12 months.

Read more 
Funding to accelerate delivery of Univercells' vaccine portfolio

Funding to accelerate delivery of Univercells' vaccine portfolio

11 Oct 2019

European financing to support Univercells’ R&D investments to develop four essential and undersupplied global health vaccines to be produced at affordable prices, high quality and large volumes.

Read more 
Industrial-scale manufacture of therapeutic exosomes

Industrial-scale manufacture of therapeutic exosomes

10 Oct 2019

Coordinated purification process development service accelerates progress to clinical trials, and scale-up manufacturing.

Read more 
BASF and Biomillenia join forces in microbiome research to promote healthy skin

BASF and Biomillenia join forces in microbiome research to promote healthy skin

7 Oct 2019

Research aims to identify novel dermocosmetic active ingredients via unique microbiome-on-a-chip technology.

Read more 
Arctoris secures funding to advance novel robotic drug discovery platform

Arctoris secures funding to advance novel robotic drug discovery platform

1 Oct 2019

Platform will enable scientists and biotechnology entrepreneurs worldwide to make discoveries faster and more efficiently,

Read more 
Data on lead ADC demonstrates effective tumour regression

Data on lead ADC demonstrates effective tumour regression

1 Oct 2019

IKS01 shows marked anti-tumour efficacy in pre-clinical models of ovarian and lung cancer.

Read more 
Researchers develop less toxic anti-cancer drug

Researchers develop less toxic anti-cancer drug

24 Sep 2019

New drug works like a ‘magic bullet’ that is delivered directly to the mitochondria of cancer cells.

Read more 
EC approves its first plant-derived cannabis-based medicine

EC approves its first plant-derived cannabis-based medicine

24 Sep 2019

Epidyolex (cannabidiol) approved for the treatment of seizures in patients with two rare, severe forms of childhood-onset epilepsy.

Read more